Role of Bone Marrow Niche in Haematological Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 1647

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK
Interests: cellular biology; mesenchymal stem cells; bone marrow microenvironment; cancer immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Blood cancers include leukaemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative syndromes.  These cancers are extremely challenging with great patient variability in molecular and clinical profiles. The treatment failure and adverse side effects of intensive therapies, particularly bone marrow transplantation, are other demands to increase research in this field. Bone marrow niches for these haematological cancers include different cells of blood and stromal types. Many genetics and functional cell studies have focused on malignant blast cells and cancer immunology. However, there is a need for novel research to understand the complicated pathogenesis of these cancers and identify new roles of related molecules and signalling.  Such knowledge is needed to improve current treatment options and develop new therapeutic tools.

This Special Issue will cover a wide range of research on the cellular and molecular mechanisms of blood cancers, particularly those taking place within the bone marrow microenvironment. We welcome submissions of original research or review articles on, but not limited to, the following topics:

  • Immune, stromal, and hematopoietic malignant cellular interactions.
  • Molecules within the bone marrow microenvironment.
  • Oncogenic pathways in bone marrow driving blood cancer progress.
  • Biotechnology, therapeutic tools, or biomaterials to model or target the blood cancer microenvironment.

Dr. Jehan J. El-Jawhari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood cancers
  • bone marrow
  • microenvironment
  • immune stromal interactions
  • mesenchymal stem cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 3239 KiB  
Review
Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia
by Ilayda Eroz, Prabneet Kaur Kakkar, Renal Antoinette Lazar and Jehan El-Jawhari
Biomedicines 2024, 12(8), 1677; https://doi.org/10.3390/biomedicines12081677 - 26 Jul 2024
Viewed by 977
Abstract
Mesenchymal stem cells (MSCs) are one of the main residents in the bone marrow (BM) and have an essential role in the regulation of haematopoietic stem cell (HSC) differentiation and proliferation. Myelodysplastic syndromes (MDSs) are a group of myeloid disorders impacting haematopoietic stem [...] Read more.
Mesenchymal stem cells (MSCs) are one of the main residents in the bone marrow (BM) and have an essential role in the regulation of haematopoietic stem cell (HSC) differentiation and proliferation. Myelodysplastic syndromes (MDSs) are a group of myeloid disorders impacting haematopoietic stem and progenitor cells (HSCPs) that are characterised by BM failure, ineffective haematopoiesis, cytopenia, and a high risk of transformation through the expansion of MDS clones together with additional genetic defects. It has been indicated that MSCs play anti-tumorigenic roles such as in cell cycle arrest and pro-tumorigenic roles including the induction of metastasis in MDS and leukaemia. Growing evidence has shown that MSCs have impaired functions in MDS, such as decreased proliferation capacity, differentiation ability, haematopoiesis support, and immunomodulation function and increased inflammatory alterations within the BM through some intracellular pathways such as Notch and Wnt and extracellular modulators abnormally secreted by MSCs, including increased expression of inflammatory factors and decreased expression of haematopoietic factors, contributing to the development and progression of MDSs. Therefore, MSCs can be targeted for the treatment of MDSs and leukaemia. However, it remains unclear what drives MSCs to behave abnormally. In this review, dysregulations in MSCs and their contributions to myeloid haematological malignancies will be discussed. Full article
(This article belongs to the Special Issue Role of Bone Marrow Niche in Haematological Cancers)
Show Figures

Figure 1

Back to TopTop